Table 3.
Characteristics and TIPS-related complications in Group A
| Characteristics | n | % |
|---|---|---|
| Transhepatic approach | ||
| No/yes | 40/2 | 95.2/4.8 |
| Arterioportal fistula | ||
| No/yes | 40/2 | 95.2/4.8 |
| TIPS-revision | ||
| No/yes | 39/3 | 92.9/7.1 |
| Coronary vein embolisation | ||
| No/yes | 11/31 | 26.2/73.8 |
| PPG (mmHg) † | ||
| Before TIPS | 25.2 ± 6.29 | |
| After TIPS | 10.8 ± 6.59 | |
| Reducing | 14.3 ± 4.31 | |
| Systemic therapy | ||
| Sorafenib/lenvatinib | 23/19 | 54.8/45.2 |
| Regorafenib | 5 | 11.9 |
| TIPS-related complications | ||
| Intraperitoneal haemorrhage | 1 | 2.4 |
| Bile duct injury | 1 | 2.4 |
| Hepatic encephalopathy | ||
| Mild/moderate/severe | 2/2/1 | 4.8/4.8/2.4 |
| Abnormal liver function after TIPS creation | 2 | 4.8 |
Notes: † mean ± standard deviation; Unless otherwise indicated, data are the number of patients, with percentages in parentheses; Group A, TIPS plus sequential systemic therapy
Abbreviations: TIPS transjugular intrahepatic portosystemic shunt, PPG portal venous pressure gradient